These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12144543)

  • 1. Severe cardiac toxicity after monoclonal antibody therapy.
    Damaj G; Rubio MT; Audard V; Hermine O
    Eur J Haematol; 2002 May; 68(5):324. PubMed ID: 12144543
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiac involvement with mycosis fungoides: could this explain alemtuzumab toxicity?
    Sleigh KA; Smith ME; Rule SA
    Leuk Lymphoma; 2008 Oct; 49(10):2022-4. PubMed ID: 18452071
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.
    Lenihan DJ; Alencar AJ; Yang D; Kurzrock R; Keating MJ; Duvic M
    Blood; 2004 Aug; 104(3):655-8. PubMed ID: 15073032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.
    Enblad G; Hagberg H; Erlanson M; Lundin J; MacDonald AP; Repp R; Schetelig J; Seipelt G; Osterborg A
    Blood; 2004 Apr; 103(8):2920-4. PubMed ID: 15070664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study.
    Kim SJ; Kim K; Kim BS; Suh C; Huh J; Ko YH; Kim WS
    Ann Oncol; 2009 Feb; 20(2):390-2. PubMed ID: 19211502
    [No Abstract]   [Full Text] [Related]  

  • 6. Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab.
    Zeitlinger MA; Schmidinger M; Zielinski CC; Chott A; Raderer M
    Leuk Lymphoma; 2005 May; 46(5):771-4. PubMed ID: 16019517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.
    Zinzani PL; Alinari L; Tani M; Fina M; Pileri S; Baccarani M
    Haematologica; 2005 May; 90(5):702-3. PubMed ID: 15921394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vivo purging of the circulating clonal T-cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation.
    Shustov A; Cherian S; Shaw A; Lupinacci TA; Maloney D; Holmberg L; Gopal AK
    Br J Haematol; 2011 Aug; 154(3):415-8. PubMed ID: 21488858
    [No Abstract]   [Full Text] [Related]  

  • 9. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
    Kim JG; Sohn SK; Chae YS; Cho YY; Yang DH; Lee JJ; Kim HJ; Shin HJ; Chung JS; Cho GJ; Lee WS; Joo YD; Sohn CH; Oh SJ
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):129-34. PubMed ID: 17406867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
    Amengual JE; Raphael BG
    Leuk Lymphoma; 2010 Jul; 51(7):1347-50. PubMed ID: 20572801
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab.
    Fietz T; Thiel E
    Recent Results Cancer Res; 2007; 176():153-63. PubMed ID: 17607923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.
    Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Lisa F; Fierro MT
    Haematologica; 2007 Jun; 92(6):784-94. PubMed ID: 17550851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
    Thieblemont C; Bouafia F; Hornez E; Dumontet C; Tartas S; Antal D; Lemieux B; Traullé C; Espinouse D; Salles G; Coiffier B
    Leuk Lymphoma; 2004 Apr; 45(4):711-4. PubMed ID: 15160944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Zent CS
    Leuk Lymphoma; 2008 Feb; 49(2):175-6. PubMed ID: 18231900
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy.
    Yi JH; Kim SJ; Ko YH; Kim WS
    Leuk Lymphoma; 2011 Feb; 52(2):317-20. PubMed ID: 21067447
    [No Abstract]   [Full Text] [Related]  

  • 17. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.
    Sefcick A; Sowter D; DasGupta E; Russell NH; Byrne JL
    Br J Haematol; 2004 Feb; 124(4):558-9. PubMed ID: 14984510
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma.
    Soldini D; Mora O; Cavalli F; Zucca E; Mazzucchelli L
    Br J Haematol; 2008 Jul; 142(3):484-6. PubMed ID: 18510686
    [No Abstract]   [Full Text] [Related]  

  • 19. DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab.
    d'Arena G; de Filippi R; Pinto A
    Leuk Lymphoma; 2007 Mar; 48(3):625-7. PubMed ID: 17454610
    [No Abstract]   [Full Text] [Related]  

  • 20. Expression of CD52 in peripheral T-cell lymphoma.
    Piccaluga PP; Agostinelli C; Righi S; Zinzani PL; Pileri SA
    Haematologica; 2007 Apr; 92(4):566-7. PubMed ID: 17488672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.